• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Early ivermectin treatment does not lower Covid-19 related hospitalizations

byDavid XiangandHarsh Shah
May 13, 2022
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Ivermectin treatment did not lower the incidence of medical admission to a hospital due to the progression of Covid-19.

2. Ivermectin treatment did not reduce the length of observation in the emergency department in patients with an early diagnosis of Covid-19.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Identifying inexpensive, widely available, and effective therapies for Covid-19 is important, as major challenges remain regarding vaccine production and allocation. Ivermectin, which is typically used as an antiparasitic drug, has been proposed to have efficacy for the treatment of Covid-19, though previously has been used for the treatment of onchocerciasis, strongyloidiasis, and ectoparasitic infection. Therefore, there is a gap in knowledge as to understanding the efficacy of ivermectin for the prevention of progression of Covid-19 resulting in hospitalization among outpatients with SARS-CoV-2 infection. This study found that administration of ivermectin did not result in a lower incidence of hospitalization or prolonged emergency department observation for Covid-19. This study was limited by potential criticism that the study’s administration regimen was inadequate given the public interest in ivermectin and the support of its use by paramedical groups. Nevertheless, these study’s findings are significant, as they demonstrate that early treatment of Covid-19 patients with ivermectin does not result in a lower incidence of hospital admission or prolonged emergency department observation for patients at high risk for serious illness.

Click to read the study in NEJM

Relevant Reading: Toxic Effects from Ivermectin Use Associated with Prevention and Treatment of Covid-19

In-Depth [randomized clinical trial]: This double-blind, randomized, placebo-controlled, adaptive platform trial studied Covid-19 positive patients from 12 public health clinics in Brazil. Patients who were 18 years or older, and presented to an outpatient clinic with symptoms of Covid-19, and at least one high-risk criterion for progression of Covid-19 such as diabetes mellitus, hypertension, lung disease, or cardiovascular disease were eligible for the study. Patients who were previously vaccinated against Covid-10 were also eligible for the study. Patients who did not have at least one high-risk criterion for Covid-19 progression were excluded from the study. The primary outcome measured was hospitalization due to Covid-19 within 28 days after randomization or an emergency department visit due to worsening of Covid-19 symptoms within 28 days after randomization. Outcomes in the primary analysis were assessed via an intention-to-treat population and a Bayesian framework. Based on the analysis, this study randomly assigned 3515 patients to receive ivermectin, placebo, or another intervention. Overall, 14.7% of patients in the ivermectin group had a primary outcome event such as hospitalization, while 16.3% of patients in the placebo group had a primary outcome event (relative risk, 0.9; 95% Bayesian credible interval, 0.7 to 1.16). 81% of these primary outcome events consisted of hospital admissions. These findings were similar to a modified intention-to-treat analysis that included patients who received at least one dose of ivermectin or placebo (relative risk, 0.89; 95% Bayesian credible interval, 0.69 to 1.15). In a per-protocol analysis that included patients who were 100% adherent to their assigned regimen, the findings were similar as well, with a relative risk of 0.94 (95% Bayesian credible interval, 0.67 to 1.35). Overall, this study demonstrates that early ivermectin treatment does not significantly reduce the incidence of hospital admission or prolonged emergency department observation for outpatients with an early diagnosis of Covid-19 and at high risk for serious illness or disease progression.

RELATED REPORTS

Online cooking education may improve perceived cooking and motor competencies in children

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

2 Minute Medicine Rewind January 23, 2023

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: CoronavirusCOVID-19hospitalizationinpatient hospitalizationivermectinSARS-CoV-2
Previous Post

Time restricted eating not more beneficial than daily calorie restriction

Next Post

CT associated with lower complication risks than invasive coronary angiography

RelatedReports

Eating in the absence of hunger linked to toddler obesity
Lifestyle

Online cooking education may improve perceived cooking and motor competencies in children

January 31, 2023
Social networks play key roles in parental vaccination decisions
Infectious Disease

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

January 30, 2023
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Weekly Rewinds

2 Minute Medicine Rewind January 23, 2023

January 30, 2023
Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Unvaccinated status increases risk of long COVID symptoms

January 25, 2023
Next Post
PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study

CT associated with lower complication risks than invasive coronary angiography

Clinical practice guidelines linked to improved bronchiolitis outcomes

Respiratory syncytial virus (RSV) vaccine produces transplacental neutralizing antibodies in pregnant women

Novel coronavirus identified from patients with pneumonia in Wuhan, China

Fourth BNT162b2 vaccine dose provides short-term effectiveness against Covid-19 related outcomes

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Gender-affirming hormones improve psychosocial functioning in transgender youth
  • Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients
  • #VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options